GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (HKSE:06929) » Definitions » Net Change in Cash

OrbusNeich Medical Group Holdings (HKSE:06929) Net Change in Cash : HK$-351 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is OrbusNeich Medical Group Holdings Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

OrbusNeich Medical Group Holdings's Net Change in Cash for the six months ended in Jun. 2024 was HK$-216 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-351 Mil.

OrbusNeich Medical Group Holdings Net Change in Cash Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings Net Change in Cash Chart

OrbusNeich Medical Group Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
-1.41 11.48 1,253.88 -694.77 -221.75

OrbusNeich Medical Group Holdings Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only -347.41 -350.13 -87.20 -134.81 -216.46

OrbusNeich Medical Group Holdings Net Change in Cash Calculation

OrbusNeich Medical Group Holdings's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=179.875+-408.57+6.904+0.039
=-222

OrbusNeich Medical Group Holdings's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=64.128+-171.961+-96.906+-11.723
=-216

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-351 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OrbusNeich Medical Group Holdings Net Change in Cash Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

OrbusNeich Medical Group Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (HKSE:06929) » Definitions » Net Change in Cash
Comparable Companies
HKSE:03600 HKSE:01358 HKSE:01501 HKSE:01120 HKSE:01406 HKSE:01947 HKSE:00876 HKSE:08513 HKSE:01134 HKSE:00907 ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 OCSE:COLO B XSWX:STMN XPAR:DIM
Traded in Other Exchanges
N/A
Address
3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG
Website
https://www.orbusneich.com
OrbusNeich is a China-based global medical device maker of endovascular interventional instruments with global reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's largest revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its largest product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.
Executives
Harmony Tree Limited 2101 Beneficial owner
Shenzhen Capital Group Co., Ltd. 2201 Interest of corporation controlled by you
Suzhou Red Earth Yeju Investment Ltd. 2101 Beneficial owner
Chien David 2201 Interest of corporation controlled by you
Lau Kwai Ching Denise 2201 Interest of corporation controlled by you
Shen Chuang Tou Zhi Zao Ye Zhuan Xing Sheng Ji Xin Cai Liao Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Shen Chuang Tou Hong Tu Si Mu Gu Quan Tou Zi Ji Jin Guan Li Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Hong Tu Ye Ju Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you

OrbusNeich Medical Group Holdings Headlines

No Headlines